Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Just For You Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech SectorAuthor: Jeffrey Neal Johnson. First Published: 2/24/2026. 
In Brief - Johnson & Johnson has maintained an impressive streak of increasing its dividend payouts for generations, rewarding long-term shareholders with reliable income.
- Management is driving future expansion by focusing on high-growth pharmaceutical assets and cutting-edge medical technologies, such as robotics.
- Investors looking for shelter from market volatility benefit from a stock that historically moves much less than the broader market indices.
While the technology sector is again experiencing volatility from artificial intelligence–driven scare trades and valuation worries, a different story is playing out in the healthcare sector. Investors fleeing the jittery price swings of high‑growth tech stocks are finding shelter in a familiar name that is quietly outperforming. Johnson & Johnson (NYSE: JNJ) is trading near all‑time highs around $245 per share, a divergence that has drawn Wall Street's attention. This rally runs counter to the perception of the healthcare giant as a slow, boring stock. Over the last 30 days, shares have climbed roughly 14%, substantially outperforming the broader market during a period of uncertainty. That price action suggests institutional money is rotating out of riskier assets and placing a premium on stability, consistent cash flow, and operational execution. For investors watching the tape on Feb. 24, 2026, note a specific calendar event: today is the ex‑dividend date for Johnson & Johnson. The stock price will likely drop by the amount of the upcoming dividend, $1.30 per share — a mechanical market adjustment rather than a reflection of business performance. For income‑focused investors, this technical dip often represents an attractive entry point instead of a sell signal. 64 Years of Unbroken Growth The primary case for holding Johnson & Johnson through turbulent market cycles is its financial strength and role as a portfolio stabilizer. The company is part of an elite group known as Dividend Kings — firms that have increased their dividends for at least 50 consecutive years. Johnson & Johnson has raised its dividend for 64 consecutive years, a record that spans multiple recessions, market crashes, and geopolitical shocks. That reliability is rare in a market focused on speculative growth. The stock currently yields about 2.12%, based on an annual payout of $5.20 per share. While higher yields exist in bonds or riskier sectors, J&J's appeal lies in its mix of growth and safety. The dividend is supported by a sizable liquidity cushion: management projects free cash flow of roughly $21 billion in 2026. That cash generation helps ensure the company can continue paying shareholders, invest in R&D, and manage legal expenses without heavy borrowing. For risk‑averse investors, an especially compelling metric is the stock's Beta. Beta measures how much a stock moves compared with the overall market (S&P 500). A Beta of 1.0 moves in step with the market; Johnson & Johnson's Beta is just 0.35 — about 65% less volatile historically. When tech stocks swing wildly, JNJ tends to hold its ground. Adding JNJ to a tech‑heavy portfolio acts as a mathematical shock absorber, damping overall volatility while preserving equity exposure. Beyond the Patent Cliff: The Road to $100 Billion Safe stocks often get stereotyped as non‑growth names. Johnson & Johnson is disproving that with a strategic pivot that appears to be paying off. Management projects full‑year revenue for 2026 to exceed the $100 billion mark for the first time in company history, with adjusted earnings per share near $11.53. That growth stems from a reinvigorated pharmaceutical division, now branded Innovative Medicine. Investors had worried about the patent cliff for Stelara, a blockbuster immunology drug that lost exclusivity in 2025. Typically, such losses dent revenue materially. J&J has offset that decline with the rapid growth of new blockbusters. Two key assets are driving this resilience: - Darzalex: This oncology franchise generates roughly $14 billion in annual sales and has become foundational in multiple myeloma treatment worldwide.
- Tremfya: Positioned as a successor to Stelara, Tremfya recently reported strong three‑year remission data for ulcerative colitis — evidence the company can defend market share in a competitive immunology space.
The Tech in MedTech: High‑Margin Technologies Growth extends beyond pharmaceuticals into MedTech. That division has shifted toward higher‑growth, higher‑margin technologies, highlighted by the integration of Shockwave Medical to modernize the cardiovascular portfolio. Shockwave's intravascular lithotripsy (IVL) uses sonic pressure waves to break up calcified plaque in arteries, a major upgrade over traditional angioplasty balloons — conceptually similar to how kidney stones are treated. Owning this technology gives Johnson & Johnson a high‑growth asset that complements its heart pump and surgical businesses. The company is also advancing in robotics. The submission of its Ottava robotic surgical system for FDA approval signals an intent to compete in the expanding soft‑tissue robotics market. These higher‑tech devices carry stronger profit margins and create sticky relationships with hospital systems, providing a durable earnings tailwind beyond basic consumables. Addition by Subtraction: The Orthopedics Strategy To sustain growth and improve margins, management is reshaping the corporate portfolio. A major development is the potential separation or sale of the DePuy Synthes orthopedics business. Originally planned as a spin‑off, reports now suggest the company is exploring a mega‑sale of the unit. Divesting orthopedics is an example of addition by subtraction. Orthopedics is a mature, lower‑growth business compared with the surging fields of oncology and cardiovascular devices. Shedding the unit would boost overall revenue growth and margins, and a sale could generate a substantial cash inflow — potentially billions — to fund acquisitions, share buybacks, or other strategic uses. Legal risks remain part of the analysis. Johnson & Johnson continues to face litigation over talc‑based products, including a recent $1.5 billion verdict that keeps the issue in the headlines. A commercial lawsuit from Bayer over marketing claims for prostate cancer drugs has also added noise. Still, the stock's recent rally suggests many investors are looking past the headlines. The prevailing bullish view is that J&J has the financial depth to manage these liabilities without disrupting operations. With roughly $20+ billion in cash and marketable securities, potential proceeds from an orthopedics sale, and about $21 billion in annual free cash flow, the company has a financial cushion that can absorb settlements — keeping legal matters as balance‑sheet items rather than existential threats to the dividend or business. Capital Preservation With Upside Johnson & Johnson has evolved from a slow‑moving conglomerate into a more focused, technology‑forward healthcare company. By divesting its consumer health division (Kenvue (NYSE: KVUE)) and potentially its orthopedics unit, the company is streamlining operations to concentrate on higher‑growth pharmaceuticals and medical technology. While JNJ is no longer a deep‑value bargain — trading near all‑time highs — it offers a compelling blend of capital preservation and growth. The combination of a 64‑year dividend growth streak, a notably low volatility profile, and a credible path to $100 billion in revenue makes it an attractive option for 2026. For investors tired of technology's unpredictability, Johnson & Johnson demonstrates that, in this market, boring can be both beautiful and profitable.
| 
